Sign In
Buy MRNA
$51.59
+2.53 (+5.16%)
At Close: Jun 04, 2026
3 Health Care Stocks In Great Financial Health
02:02pm, Wednesday, 03'rd Aug 2022 Investing.com
Pre-markets Green on Strong Earnings Numbers
01:44pm, Wednesday, 03'rd Aug 2022 Zacks Investment Research
Pre-markets Green on Strong Earnings Numbers.
Keep running with the bond bulls, says Bank of America
12:48pm, Wednesday, 03'rd Aug 2022 MarketWatch
The rally in bond markets of late has been startling. As hopes grow that inflation may have peaked, and evidence of a U.S. economic slowdown build, benchmark 10-year Treasury yields fell from around t
Moderna (MRNA) Q2 Earnings and Revenues Beat Estimates
12:25pm, Wednesday, 03'rd Aug 2022 Zacks Investment Research
Moderna (MRNA) delivered earnings and revenue surprises of 16.44% and 22.08%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Could This Unknown Stock Beat Moderna in 2023?
11:55am, Wednesday, 03'rd Aug 2022 The Motley Fool
Vaxart is still in the coronavirus vaccine race, even though its competitors remain very far ahead.
U.S. Stock Futures Gain Ahead of Services PMI; Crude Oil Drops Over 1%
10:06am, Wednesday, 03'rd Aug 2022 Benzinga
Pre-open movers
U.S. stock futures traded higher in early pre-market trade on Wednesday after the Dow Jones dipped over 400 points in the previous session. Investors are awaiting earnings results from
Starbucks, Yum! Brands And 3 Stocks To Watch Heading Into Wednesday
08:36am, Wednesday, 03'rd Aug 2022 Benzinga
With US stock futures trading higher this morning on Wednesday ahead of earnings reports from several big companies, some of the stocks that may grab investor focus today are as follows:
Wall Street
Could the Fall Booster Market Boost Vaccine Stocks?
10:00am, Tuesday, 02'nd Aug 2022 The Motley Fool
The booster market might be a long-term source of revenue.
Why Pfizer and BioNTech Are Beating Moderna in the Omicron Booster Market
09:57am, Tuesday, 02'nd Aug 2022 The Motley Fool
Moderna is still prevailing in the omicron booster market in at least one important way.
4 Analysts Have This to Say About Moderna
05:11pm, Monday, 01'st Aug 2022 Benzinga
Over the past 3 months, 4 analysts have published their opinion on Moderna (NASDAQ:MRNA) stock. These analysts are typically employed by large Wall Street banks and tasked with understanding a company
Moderna (MRNA) to Report Q2 Earnings: What's in the Cards?
03:40pm, Monday, 01'st Aug 2022 Zacks Investment Research
Investor focus is likely to be on the progress of Moderna's (MRNA) late-stage pipeline candidates on the second-quarter earnings call that can lower its dependence on Spikevax.
Could This News Change Everything for Moderna?
10:00am, Monday, 01'st Aug 2022 The Motley Fool
Moderna's blockbuster product is set for a new wave of demand.
Moderna and Pfizer to start clinical trials for COVID-19 boosters that target BA.5 'in the near future'
03:36pm, Sunday, 31'st Jul 2022 MarketWatch
'We need vaccines with longer duration and greater breadth of protection,' said Dr. David Kessler, chief science officer for the White House’s COVID-19 response team.
Big Tech survived the earnings test, but many more tech companies are picking up their pencils
01:00pm, Sunday, 31'st Jul 2022 MarketWatch
Wall Street breathed a sigh of relief this week after Big Tech produced results that were largely not as bad as feared (except for Facebook), but the harder part of this earnings season may arrive in
